Comments on: “Meta-analysis of association between Arg326Gln (rs1503185) and Gln276Pro (rs1566734) polymorphisms of PTPRJ gene and cancer risk”
Laczmanska (Laczmanska and Sasiadek 2019) recently published a meta-analysis about the association of two polymorphisms in PTPRJ gene (Arg326Gln (rs1503185) and Gln276Pro (rs1566734)) and different types of cancers. They concluded that “the polymorphisms Arg326Gln and Gln276Pro of the PTPRJ gene are not associated with an increased risk of cancer except for the Arg326Gln polymorphism in colorectal cancer”. Their study showed non-significant results for Arg326Gln 1.18(0.94–1.47) and Gln276Pro 1.04(0.96–1.12) in cancer overally and in different subgroup based on the type of cancers. However, there are some misinterpretations in the meta-analysis which should be noticed. Here we aim to comment on the issue and the correct results.
- Iuliano R, Palmieri D, He H et al (2010) Role of PTPRJ genotype in papillary thyroid carcinoma risk. Endocr Relat Cancer. https://doi.org/10.1677/ERC-10-0143
- Mita Y, Yasuda Y, Sakai A et al (2010) Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-009-0656-7
- Toland AE, Rozek LS, Presswala S et al (2008) PTPRJ haplotypes and colorectal cancer risk. Cancer Epidemiol Biomark Prev. https://doi.org/10.1158/1055-9965.EPI-08-0513
- van Puijenbroek M, Dierssen JWF, Stanssens P et al (2005) Mass spectrometry-based loss of heterozygosity analysis of single-nucleotide polymorphism loci in paraffin embedded tumors using the MassEXTEND assay: single-nucleotide polymorphism loss of heterozygosity analysis of the protein tyrosine phosphatase receptor type J in familial colorectal cancer. J Mol Diagn 7(5):623–630. https://doi.org/10.1016/S1525-1578(10)60596-X CrossRefGoogle Scholar